Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

By Global News Feed

MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Tuesday, April 16 and Wednesday, April 17, 2024. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent’s business and corporate activities on Wednesday, April 17 at 3:30pm EDT.

View post:
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

By Global News Feed

FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is set to receive $50,000,000 as licensing fees in the form of Cash/Shares within 30 days of execution of the Definitive Agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and Royalties of 5% of net sales, up to $50,000,000, after the launch of the Licensed Products.

See the rest here:
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung…

By Global News Feed

OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer

Continue reading here:
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung...

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR…

By Global News Feed

Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers

The rest is here:
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR...

Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists

By Global News Feed

SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced that Amber Salzman, Ph.D., chief executive officer, participated in a fireside chat at the Canaccord Genuity - Genetic Medicine for Generalists Fireside Chat today.

See the rest here:
Epic Bio to Participate in a Fireside Chat at the Canaccord Genuity Genetic Medicine for Generalists

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

By Global News Feed

ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations. Mr. Nassif joins Pharvaris with more than 30 years of experience in financial management, strategic planning, mergers and acquisitions, investor relations, legal, and capital allocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies.

Read the rest here:
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

→←